MERIBEL PHARMA SOLUTIONS

What this means for you

Not registered yet, but its 19 Nov 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

98860857

Mark type

Stylized text

Filed

19 Nov 2024

Attorney of record

Amy A. Abeloff

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations; biological preparations; pharmaceutical substances and preparations; vaccines; vaccine manufacturing preparations; reagents for medical use; diagnostic preparations; diagnostic reagents for medical use; biological preparations for the treatment of cancer; biological preparations for the treatment of viral infections; biological preparations for the treatment of autoimmune diseases; biological preparations for medical use; immunotherapeutic drugs; therapeutic and prophylactic pharmaceutical products; gene therapy products; pharmaceuticals in the form of nanoparticles for delivery; pharmaceutical substances and preparations, nanoparticles, viral vectors, retroviral vectors, lentiviral vectors and non-viral vectors for the delivery of genes to cells, all for medical purposes; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders
• Class 040 — Treatment of materials: Custom manufacture of pharmaceuticals; custom manufacture of medicines and vaccines; custom manufacture of products relating to biotechnology; custom manufacture of pharmaceuticals and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; custom manufacture of gene therapy, and viral, retroviral, lentiviral and non-viral preparations and biopharmaceutical products; contract manufacturing services; pharmaceutical contract manufacturing services; biotechnology contract manufacturing services; contract manufacture of pharmaceuticals and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; contract manufacture of gene therapy, and viral, retroviral, lentiviral and non-viral preparations and biopharmaceutical products
• Class 042 — Scientific and technological services: Scientific and technological services and research and design relating thereto; industrial analysis services; laboratory services; research and development services; pharmaceutical research and development services; research and development in the biotechnology field; biological research, clinical research and medical research; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals; conducting clinical trials; pharmaceutical testing and clinical trials; pharmaceutical drug developments services; research and development of pharmaceutical preparations; research and development of vaccines and medicines; research and development of gene-based medicines; research and laboratory analytic and diagnostic services; design of manufacturing facilities; manufacturing development services; quality control and validation services; genetic engineering laboratories and biochemistry laboratories; product development consultancy in the field of pharmaceuticals; product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; product, viral vector and analytic assay development for others; product development consultancy in the field of pharmaceuticals and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; product development consultancy in the field of gene therapy, and viral, retroviral, lentiviral and non-viral preparations and biopharmaceutical products; provision of information relating to scientific research; provision of scientific information; research and scientific analysis relating to drug discovery and development for others; scientific advisory services; scientific consultancy; pharmaceutical consultancy; management of scientific research projects; management of pharmaceutical projects; issuing of scientific information; provision of information and consultancy in relation to the aforesaid services

Owner

• BW CDMO Holdings UK Limited, London, GB

Prosecution history

• 17 Jan 2026 — NOTIFICATION OF PRIORITY ACTION E-MAILED
• 17 Jan 2026 — PRIORITY ACTION E-MAILED
• 17 Jan 2026 — PRIORITY ACTION WRITTEN
• 11 Nov 2025 — EXAMINER'S AMENDMENT ENTERED
• 11 Nov 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
• 11 Nov 2025 — EXAMINERS AMENDMENT E-MAILED
• 11 Nov 2025 — EXAMINERS AMENDMENT -WRITTEN
• 19 Aug 2025 — NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
• 19 Aug 2025 — INQUIRY TO SUSPENSION E-MAILED
• 19 Aug 2025 — SUSPENSION INQUIRY WRITTEN
• 19 Aug 2025 — NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
• 19 Aug 2025 — INQUIRY TO SUSPENSION E-MAILED
• 19 Aug 2025 — SUSPENSION INQUIRY WRITTEN
• 17 Jul 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 17 Jul 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE